To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of HIFU and adebrelimab.
Breast Cancer|HR+/HER2- Breast Cancer
DRUG: Adebrelimab|PROCEDURE: High Intensity Focused Ultrasoun（HIFU）|DRUG: Cyclophosphamide|DRUG: Epirubicin|DRUG: Docetaxel
tpCR, total pathologic complete response rate（lymph node and breast）, 6 months
bpCR, breast pathologic complete response rate, 6 months
To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of HIFU and adebrelimab.